The active metabolite of leflunomide, A771726, increases proliferation of human synovial fibroblasts in presence of IL-1β and TNF-α

Inflammation Research

Volumn 55, Issue 11, 2006, Pages 469-475

  Magne, D ^a,b,c   Mezin F ^a,b   Palmer, G ^a,b   Guerne, P A ^a,b  

^a UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF GENEVA   (Switzerland)

^c Biomaterials and Biotechnologies   (France)

Author keywords

Cyclooxygenase; Leflunomide; Proliferation; Rheumatoid arthritis; Synovial fibroblast

Indexed keywords

INDOMETACIN; INTERLEUKIN 1BETA; LEFLUNOMIDE; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; PROTEIN TYROSINE KINASE; TERIFLUNOMIDE; THYMIDINE; TRITIUM; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CELL COUNT; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME INHIBITION; FIBROBLAST; HUMAN; HUMAN CELL; HUMAN TISSUE; MITOGENESIS; SYNOVIUM;

ANILINE COMPOUNDS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, RHEUMATOID; CELL PROLIFERATION; CELLS, CULTURED; DRUG SYNERGISM; ENZYME INHIBITORS; FIBROBLASTS; HUMANS; HYDROXYBUTYRATES; INTERLEUKIN-1BETA; ISOXAZOLES; JURKAT CELLS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROTEIN-TYROSINE KINASES; SYNOVIAL MEMBRANE; TUMOR NECROSIS FACTOR-ALPHA; URIDINE;

EID: 37849185758     PISSN: 10233830     EISSN: 1420908X     Source Type: Journal    
DOI: 10.1007/s00011-006-5196-x     Document Type: Article

References (36)

1. Sanders S, Harisdangkul V. Leflunomide for the treatment of rheumatoid arthritis and autoimmunity. Am J Med Sci 2002; 323: 190-3.
2. Strand V, Cohen S, Schiff M, Weaver A, Fleischmann R, Cannon G, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med 1999; 159: 2542-50.
3. van Roon EN, Yska JP, Raemaekers J, Jansen TL, van Wanrooy M, Brouwers JR. A rapid and simple determination of A771726 in human serum by high-performance liquid chromatography and its application for optimization of leflunomide therapy. J Pharm Biomed Anal 2004; 36: 17-22.
4. van Roon EN, Jansen TL, van de Laar MA, Janssen M, Yska JP, Keuper R, et al. Therapeutic drug monitoring of A771726, the active metabolite of leflunomide: serum concentrations predict response to treatment in patients with rheumatoid arthritis. Ann Rheum Dis 2005; 64: 569-74.
5. Breedveld FC, Dayer JM. Leflunomide: mode of action in the treatment of rheumatoid arthritis. Ann Rheum Dis 2000; 59: 841-9.
6. Fairbanks LD, Bofill M, Ruckemann K, Simmonds HA. Importance of ribonucleotide availability to proliferating T-lymphocytes from healthy humans. Disproportionate expansion of pyrimidine pools and contrasting effects of de novo synthesis inhibitors. J Biol Chem 1995; 270: 29682-9.
7. Zielinski T, Zeitter D, Muller S, Bartlett RR. Leflunomide, a reversible inhibitor of pyrimidine biosynthesis? Inflamm Res 1995; 44 Suppl 2: S207-8.
8. Hamilton LC, Vojnovic I, Warner TD. A771726, the active metabolite of leflunomide, directly inhibits the activity of cyclooxygenase-2 in vitro and in vivo in a substrate-sensitive manner. Br J Pharmacol 1999; 127: 1589-96.
9. Xu X, Williams JW, Bremer EG, Finnegan A, Chong AS. Inhibition of protein tyrosine phosphorylation in T cells by a novel immunosuppressive agent, leflunomide. J Biol Chem 1995; 270: 12398-403.
10. Elder RT, Xu X, Williams JW, Gong H, Finnegan A, Chong AS. The immunosuppressive metabolite of leflunomide, A771726, affects murine T cells through two biochemical mechanisms. J Immunol 1997; 159: 22-7.
11. Goldring SR. Pathogenesis of bone and cartilage destruction in rheumatoid arthritis. Rheumatology (Oxford) 2003; 42 Suppl 2: ii11-6.
12. Pap T, Muller-Ladner U, Gay RE, Gay S. Fibroblast biology. Role of synovial fibroblasts in the pathogenesis of rheumatoid arthritis. Arthritis Res 2000; 2: 361-7.
13. Yamanishi Y, Firestein GS. Pathogenesis of rheumatoid arthritis: the role of synoviocytes. Rheum Dis Clin North Am 2001; 27: 355-71.
14. Takayanagi H, Juji T, Miyazaki T, Iizuka H, Takahashi T, Isshiki M, et al. Suppression of arthritic bone destruction by adenovirus-mediated csk gene transfer to synoviocytes and osteoclasts. J Clin Invest 1999; 104: 137-46.
15. Burger D, Begue-Pastor N, Benavent S, Gruaz L, Kaufmann MT, Chicheportiche R, et al. The active metabolite of leflunomide, A771726, inhibits the production of prostaglandin E(2), matrix metalloproteinase 1 and interleukin 6 in human fibroblast-like synoviocytes. Rheumatology (Oxford) 2003; 42: 89-96.
16. Kusunoki N, Yamazaki R, Kawai S. Induction of apoptosis in rheumatoid synovial fibroblasts by celecoxib, but not by other selective cyclooxygenase 2 inhibitors. Arthritis Rheum 2002; 46: 3159-67.
17. Gabay C. Cytokine inhibitors in the treatment of rheumatoid arthritis. Expert Opin Biol Ther 2002; 2: 135-49.
18. Guicheux J, Palmer G, Relic B, Mezin F, Caverzasio J, Apostolides P, et al. Primary human articular chondrocytes, dedifferentiated chondrocytes, and synoviocytes exhibit differential responsiveness to interleukin-4: correlation with the expression pattern of the common receptor gamma chain. J Cell Physiol 2002; 192: 93-101.
19. Palmer G, Burger D, Mezin F, Magne D, Gabay C, Dayer JM, et al. The active metabolite of leflunomide, A771726, increases the production of IL-1 receptor antagonist in human synovial fibroblasts and articular chondrocytes. Arthritis Res Ther 2004; 6: R181-9.
20. Palmer G, Mezin F, Juge-Aubry CE, Plater-Zyberk C, Gabay C, Guerne PA. Interferon beta stimulates interleukin 1 receptor antagonist production in human articular chondrocytes and synovial fibroblasts. Ann Rheum Dis 2004; 63: 43-9.
21. Cao WW, Kao PN, Chao AC, Gardner P, Ng J, Morris RE. Mechanism of the antiproliferative action of leflunomide. A771726, the active metabolite of leflunomide, does not block T-cell receptor-mediated signal transduction but its antiproliferative effects are antagonized by pyrimidine nucleosides. J Heart Lung Transplant 1995; 14: 1016-30.
22. Chan V, Charles BG, Tett SE. Population pharmacokinetics and association between A771726 plasma concentrations and disease activity measures following administration of leflunomide to people with rheumatoid arthritis. Br J Clin Pharmacol 2005; 60: 257-64.
23. Williams JW, Mital D, Chong A, Kottayil A, Millis M, Longstreth J, et al. Experiences with leflunomide in solid organ transplantation. Transplantation 2002; 73: 358-66.
24. Fox RI, Herrmann ML, Frangou CG, Wahl GM, Morris RE, Strand V, et al. Mechanism of action for leflunomide in rheumatoid arthritis. Clin Immunol 1999; 93: 198-208.
25. Isomaki P, Punnonen J. Pro- and anti-inflammatory cytokines in rheumatoid arthritis. Ann Med 1997; 29: 499-507.
26. Takayanagi H, Oda H, Yamamoto S, Kawaguchi H, Tanaka S, Nishikawa T, et al. A new mechanism of bone destruction in rheumatoid arthritis: synovial fibroblasts induce osteoclastogenesis. Biochem Biophys Res Commun 1997; 240: 279-86.
27. Seemayer CA, Kuchen S, Kuenzler P, Rihoskova V, Rethage J, Aicher WK, et al. Cartilage destruction mediated by synovial fibroblasts does not depend on proliferation in rheumatoid arthritis. Am J Pathol 2003; 162: 1549-57.
28. Elkayam O, Yaron I, Shirazi I, Judovitch R, Caspi D, Yaron M. Active leflunomide metabolite inhibits interleukin 1beta, tumour necrosis factor alpha, nitric oxide, and metalloproteinase-3 production in activated human synovial tissue cultures. Ann Rheum Dis 2003; 62: 440-3.
29. Berridge MV, Tan AS. Characterization of the cellular reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT): subcellular localization, substrate dependence, and involvement of mitochondrial electron transport in MTT reduction. Arch Biochem Biophys 1993; 303: 474-82.
30. Reece RJ, Kraan MC, Radjenovic A, Veale DJ, O'Connor PJ, Ridgway JP, et al. Comparative assessment of leflunomide and methotrexate for the treatment of rheumatoid arthritis, by dynamic enhanced magnetic resonance imaging. Arthritis Rheum 2002; 46: 366-72.
31. Kraan MC, Reece RJ, Barg EC, Smeets TJ, Farnell J, Rosenburg R, et al. Modulation of inflammation and metalloproteinase expression in synovial tissue by leflunomide and methotrexate in patients with active rheumatoid arthritis. Findings in a prospective, randomized, double-blind, parallel-design clinical trial in thirty-nine patients at two centers. Arthritis Rheum 2000; 43: 1820-30.
32. Kaltwasser JP, Nash P, Gladman D, Rosen CF, Behrens F, Jones P, et al. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum 2004; 50: 1939-50.
33. Reich K, Hummel KM, Beckmann I, Mossner R, Neumann C. Treatment of severe psoriasis and psoriatic arthritis with leflunomide. Br J Dermatol 2002; 146: 335-6.
34. Cohen S, Cannon GW, Schiff M, Weaver A, Fox R, Olsen N, et al. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group. Arthritis Rheum 2001; 44: 1984-92.
35. Aletaha D, Stamm T, Kapral T, Eberl G, Grisar J, Machold KP, et al. Survival and effectiveness of leflunomide compared with methotrexate and sulfasalazine in rheumatoid arthritis: a matched observational study. Ann Rheum Dis 2003; 62: 944-51.
36. Wolfe F, Michaud K, Stephenson B, Doyle J. Toward a definition and method of assessment of treatment failure and treatment effectiveness: the case of leflunomide versus methotrexate. J Rheumatol 2003; 30: 1725-32.